The Burrill Report: Pfizer's $68 Billion Buy (.MP3,8.88 Mb)

The week began with a bang when the world’s largest pharmaceutical company Pfizer announced plans to purchase Wyeth for $68 billion. The deal comes as Pfizer faces the loss of billions of dollars in revenue in the coming years as several of its blockbuster drugs go off patent and face competition from generics. Back in November, Barbara Ryan, managing director for Deutsche Bank Securities, issued a report where she said Big Pharma companies such as Pfizer would need to make precisely these types of acquisitions to address patent expirations and the massive overcapacity within the industry. We spoke to Ryan about the Pfizer deal and what other deals may be coming in its wake.